{"gao_id": "GAO-17-452", "published": "2017-05-25T12:00:00Z", "released": "2017-06-26T08:00:00Z", "summary": "Nearly 90% of the prescription drugs dispensed in the United States are generics. The Food and Drug Administration must approve these drugs before they are marketed. In 2012, a law allowed FDA to collect fees from drug manufacturers to support the review process. FDA committed to improving its process and meeting specific performance goals such as decreasing review times. We found that FDA's reliance on...", "title": "Generic Drug User Fees: Application Review Times Declined, but FDA Should Develop a Plan for Administering Its Unobligated User Fees", "topics": ["Pharmaceutical industry", "User fees", "Timeliness", "Health Care", "Communication", "Internal controls", "Prescription drugs", "Generic drugs", "Federal agencies", "Performance goals", "Information technology"], "type": "reports-testimonies", "url": "https://www.gao.gov/products/gao-17-452", "versions": [{"title": "Highlights Page (1 page)", "url": "https://www.gao.gov/assets/gao-17-452-highlights.pdf"}, {"title": "Full Report (55 pages)", "url": "https://www.gao.gov/assets/gao-17-452.pdf"}, {"title": "Accessible PDF (158 pages)", "url": "https://www.gao.gov/assets/690/685453.pdf"}]}